Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the adverse events (AEs) that can occur from nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for patients with melanoma.
Video Reports
Managing irAEs is a Dynamic Discussion
In recent years, immunotherapy agents have shown amazing success in treating patients with melanoma.
New Combos Are Coming to the Melanoma Space
There will be other drugs that will come in to the clinic. I mentioned before that T-VEC is being used in combination with pembrolizumab (Keytruda).
Dr. Daud on Dabrafenib/Trametinib Vs Immunotherapy in Melanoma
Adil Daud, MD, clinical professor, Department of Medicine (Hematology/Oncology) and director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) versus immunotherapy in patients with BRAF V600-mutant metastatic melanoma.